Nanion Technologies GmbH, a supplier of automated, parallel patch-clamp systems based in Munich, Germany, has announced that they would appeal the decision of the European Patent Office (EPO) to uphold t
Heska Corporation has announced that it has completed the sale of its rights in a worldwide patent portfolio covering a number of major allergens and the genes that encode them to
Access Pharmaceuticals, Inc has announced that the Company has received a "Notice of Allowance" letter from the United States Patent and Trademark Office for its patent application entitled "Liqu
Nano Chemical Systems announced today that it has filed a US Patent application on a breakthrough new material that exhibits light (luminescent) in the absence of heat. This Nano-enhanced
Ranbaxy Laboratories Limited announced that the Federal Court of Canada has handed down a favorable decision in the company's case against Pfizer by finding invalid Pfizer's Canadian atorvastatin pate
Thai Public Health Minister Mongkol Songkhla plans to break patents on an antiretroviral drug and a drug for heart disease by issuing compulsory licenses to produce lower-cost versions,
Access Pharmaceuticals, Inc. announced today that it was issued U.S. Patent No. 7,166,733 by the U.S. Patent and Trademark Office. This patent, entitled "O,O'-Amidomalonato and N,O-Amidom
Archus Orthopedics, Inc. has announced that the European Patent Office has confirmed the validity of its patent number EP-B-1223872 following an Opposition that concluded with oral proceedings on Ja
Nventa Biopharmaceuticals has announced that the U.S. Patent and Trademark Office has issued Patent Number 7,157,089 to Nventa.The patent provides coverage for compositions of fusion protein
The Swiss pharmaceutical giant Novartis is in court in India this week challenging the country's patent laws.The drug company is attempting to overturn the Indian government's rejection of it
Date: Thursday, 23-Nov-2006
VNUS Medical Technologies, Inc has announced that United States District Judge Maxine M. Chesney of the United States District Court for the Northern District of California issued a Markman order in the litigation brought by VNUS Medical Technologies against Diomed Holdings, Inc. and Diomed, Inc., AngioDynamics, Inc. and Vascular Solutions, Inc. (the "defendants").VNUS Medical Technologies has filed patent litigation against the defendants, alleging they infringe U.S. Patent Nos. 6,638,273, 6,258,084, 6,752,803 and 6,769,433 (the "patents-in-suit").
Markman hearings, also known as claims construction hearings, are typically held to determine the meaning of certain words or phrases in the claims of the asserted patents prior to the commencement of trial. The Court's Markman Order of November 20, 2006 addressed a number of disputed claim terms in the four patents-in-suit. The Court agreed with VNUS Medical's proposed constructions on key terms including:
The patents-in-suit are not limited to catheters with electrodes. The claim term "energy application device" refers to a device for delivering energy, including, but not limited to, RF energy, microwaves, ultrasound, direct current, circulating heating fluid, radiant light, laser and thermal energy. The claim term "effectively occlude" is properly construed as "significantly reduce the flow of blood through the treated hollow anatomical structure, including, but not limited to, full-lumen closure."Brian E. Farley, President and Chief Executive Officer, stated, "VNUS pioneered the field of endovenous treatment approximately a decade ago and has carefully developed our patent portfolio over the years. This ruling by the Court is a significant step towards the protection of our valuable intellectual property." "We are extremely pleased with the Court's Markman decision and look forward to proceeding to trial against Diomed, AngioDynamics and Vascular Solutions," said Charlene A. Friedman, Vice President and General Counsel. Trial is scheduled to begin in October 2007. VNUS Medical Technologies is seeking remedies including a permanent injunction, lost profits, royalties and enhanced damages for willfulness.
http://www.vnus.com/